Max Neeman International

15/12/2012

MPEF finally over!!!

12/12/2012

Exam time for MNI..

15/11/2011

Genzyme investigational Phase III MS drug meets co-primary endpoints

Genzyme has reported positive Phase III results of Alemtuzumab (Lemtrada) to treat multiple sclerosis (MS).

The randomized trial was designed to assess whether the investigational alemtuzumab could achieve efficacy and safety improvements over the approved interferon beta-1a (Rebif).

The trial enrolled patients who have experienced at least two relapses within the two years prior therapy .

The trial met two co-primary endpoints including a reduction in relapse rate and six months sustained accumulation of disability (SAD).

Genzyme president and CEO David Meeker said based on these positive results, they are on track to submit Lemtrada for review to US and EU regulatory authorities in the first quarter of 2012.

15/11/2011

Theravance reports COPD drug Phase 2a positive results:

Theravance has reported positive Phase 2a study results of its investigational inhaled long-acting muscarinic antagonist (LAMA) - TD-4208.

The aim of the double-blind, randomized and four-period study was to assess the bronchodilatory effect, pharmacokinetics, safety and tolerability of single inhaled doses of TD-4208 in patients with chronic obstructive pulmonary disease (COPD).

The trial enrolling 32 patients recieved TD-4208 (350 mcg and 700 mcg), ipratropium bromide and placebo, each administered as single doses via a nebulizer.

The study met the primary endpoint with a mean change from baseline in peak forced expiratory volume in one second (FEV1) compared to placebo.

The study also met the secondary endpoints, including the drug's safety and tolerability.

Theravance Research and Early Clinical Development senior vice president Mathai Mammen said they are encouraged by these positive Phase 2a results which support further development of TD-4208 in COPD.

15/11/2011

Hello folks!!!!!

Cyprotex enhanced the current PK prediction software - Cloe PK, to facilitate the drug discovery in predicting the human and rodent pharmacokinetics.

Hope this will fetch a good success rate in drug development process.

http://drugdiscovery.pharmaceutical-business-review.com/news/cyprotex-enhances-pharmacokinetic-prediction-software-platform-101111

Thanks

Cyprotex has made enhancements to its pharmacokinetic prediction software platform - Cloe PK.